RECURRENCE PATTERNS AFTER RADICAL RETROPUBIC PROSTATECTOMY: CLINICAL USEFULNESS OF PROSTATE SPECIFIC ANTIGEN DOUBLING TIMES AND LOG SLOPE PROSTATE SPECIFIC ANTIGEN
- 1 October 1997
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of Urology
- Vol. 158 (4), 1441-1445
- https://doi.org/10.1016/s0022-5347(01)64238-1
Abstract
Purpose: We studied the correlation between prostate specific antigen (PSA) doubling time or, equivalently, log slope PSA and clinical recurrence in patients with detectable PSA after radical retropubic prostatectomy who were followed expectantly. Materials and Methods: In patients with PSA recurrence after radical retropubic prostatectomy log slope PSA was determined from the difference in the 2 log PSA values divided by the time between readings in months. For a given slope the corresponding PSA doubling time was calculated as log × 2 divided by the slope of the log PSA line. When the initial PSA value was considerably greater than 0.4 ng./ml., the log slope PSA plot was extrapolated to determine the time point at which PSA would have become detectable (0.4 ng./ml.). The relationship between these values, and the time and pattern of clinical recurrence were studied. Results: In this series of 77 patients 80% with PSA doubling time of 6 months or greater remained clinically disease-free compared to 64% with PSA doubling time less than 6 months. PSA doubling time had better correlation with time to clinical recurrence after PSA became detectable (p <0.001 Cox proportional hazards model) than Gleason sum, pathological stage or margin status. Biochemical recurrence within 3 months was associated with early clinical recurrence (p <0.002). In addition, short PSA doubling time, that is a high log slope, regardless of the time at which PSA became positive was strongly associated with clinical recurrence (p <0.001). Distant recurrence was invariably associated with short PSA doubling time. Conversely, local recurrence reliably correlated with long PSA doubling time, that is a low log slope. Conclusions: After PSA became detectable PSA doubling time or, equivalently, log slope PSA, was a better indicator of the risk and time to clinical recurrence after radical retropubic prostatectomy than preoperative PSA, specimen Gleason sum or pathological stage. Hormone treatment may be targeted to patients at high risk for early metastatic clinical recurrence, appropriately timed radiation can be offered for proved local recurrence in those with long PSA doubling time and expectant treatment may be proposed for those with long PSA doubling time who remain clinically disease-free. Frequent and expensive imaging does not appear to be cost-effective in this latter group.Keywords
This publication has 18 references indexed in Scilit:
- Correlation of clinical and pathologic factors with rising prostate-specific antigen profiles after radical prostatectomy alone for clinically localized prostate cancerUrology, 1996
- Combined androgen blockade for the treatment of metastatic cancer of the prostateUrology, 1996
- Local recurrence after radical prostatectomy: Characteristics in size, location, and relationship to prostate-specific antigen and surgical marginsUrology, 1996
- Selection of men at high risk for disease recurrence for experimental adjuvant therapy following radical prostatectomyUrology, 1995
- Cancer Control and Quality of Life Following Anatomical Radical Retropubic Prostatectomy: Results at 10 YearsJournal of Urology, 1994
- 5-Year Tumor Recurrence Rates After Anatomical Radical Retropubic Prostatectomy For Prostate CancerJournal of Urology, 1994
- Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastasesUrology, 1994
- A Controlled Trial of Leuprolide with and without Flutamide in Prostatic CarcinomaThe New England Journal of Medicine, 1989
- The Value of Serum Prostate Specific Antigen Determinations Before and after Radical ProstatectomyJournal of Urology, 1989
- Prostate-Specific Antigen as a Serum Marker for Adenocarcinoma of the ProstateThe New England Journal of Medicine, 1987